SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Up 134.4% in November

SOPHiA GENETICS SA (NASDAQ:SOPH) was the target of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 56,500 shares, a growth of 134.4% from the October 31st total of 24,100 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average daily volume of 29,800 shares, the days-to-cover ratio is currently 1.9 days.

SOPHiA GENETICS Stock Up 4.3 %

SOPH traded up $0.14 during trading hours on Friday, hitting $3.41. 7,100 shares of the company’s stock were exchanged, compared to its average volume of 65,167. The company has a quick ratio of 3.59, a current ratio of 3.80 and a debt-to-equity ratio of 0.12. SOPHiA GENETICS has a 1-year low of $2.70 and a 1-year high of $7.37. The stock’s 50-day moving average is $3.50 and its two-hundred day moving average is $4.06. The stock has a market cap of $222.95 million, a price-to-earnings ratio of -3.13 and a beta of 1.03.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.04). SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. The company had revenue of $15.85 million during the quarter, compared to the consensus estimate of $15.90 million. During the same quarter in the previous year, the business earned ($0.21) EPS. Sell-side analysts predict that SOPHiA GENETICS will post -0.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of SOPH. Principal Financial Group Inc. lifted its position in SOPHiA GENETICS by 35.9% during the second quarter. Principal Financial Group Inc. now owns 1,368,378 shares of the company’s stock worth $6,267,000 after acquiring an additional 361,201 shares during the last quarter. Federated Hermes Inc. increased its position in SOPHiA GENETICS by 57.5% during the 2nd quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock worth $289,000 after buying an additional 23,000 shares during the period. Green Alpha Advisors LLC acquired a new stake in SOPHiA GENETICS in the 3rd quarter worth about $79,000. Finally, Banque Cantonale Vaudoise raised its position in shares of SOPHiA GENETICS by 300.0% in the second quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock valued at $55,000 after buying an additional 9,000 shares in the last quarter. Institutional investors and hedge funds own 31.59% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on SOPH shares. Royal Bank of Canada lowered their price target on SOPHiA GENETICS from $8.00 to $7.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Morgan Stanley downgraded shares of SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $10.00 to $5.00 in a research note on Wednesday, August 7th.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.